0001394548-17-000020.txt : 20170706 0001394548-17-000020.hdr.sgml : 20170706 20170706171916 ACCESSION NUMBER: 0001394548-17-000020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170628 FILED AS OF DATE: 20170706 DATE AS OF CHANGE: 20170706 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Galena Biopharma, Inc. CENTRAL INDEX KEY: 0001390478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4640 SW MACADAM AVENUE STREET 2: SUITE 270 CITY: PORTLAND STATE: OR ZIP: 97239 BUSINESS PHONE: 855 855 GALE MAIL ADDRESS: STREET 1: 4640 SW MACADAM AVENUE STREET 2: SUITE 270 CITY: PORTLAND STATE: OR ZIP: 97239 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: GALENA BIOPHARMA, INC. DATE OF NAME CHANGE: 20110922 FORMER COMPANY: FORMER CONFORMED NAME: RXI PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20110921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nisi Rudolph CENTRAL INDEX KEY: 0001297775 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33958 FILM NUMBER: 17953208 MAIL ADDRESS: STREET 1: TWO BALA PLAZA, SUITE 300 CITY: PHILADELPHIA STATE: PA ZIP: 19004 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2017-06-28 0 0001390478 Galena Biopharma, Inc. GALE 0001297775 Nisi Rudolph C/O GALENA BIOPHARMA, INC. 2000 CROW CANYON PL., SUITE 380 SAN RAMON CA 94583 1 0 0 0 Common Stock 2017-07-06 4 A 0 10924 0.59 A 25788 D Stock Option (right to buy) 0.55 2017-06-08 4 A 0 5000 0 A 2027-06-08 Common Stock 5000 5000 D Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. Represents the closing stock price of the Company's stock on the first trading day of the quarter. Granted pursuant to the Issuer's 2016 Incentive Plan. This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Rudolph Nisi, M.D. 2017-07-06